###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 57 62 <span type="species:ncbi:9606">women</span>
HFE H63D mutation frequency shows an increase in Turkish women with breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 322 327 <span type="species:ncbi:9606">women</span>
The hereditary hemochromatosis gene HFE plays a pivotal role in iron homeostasis. The association between cancer and HFE hetero- or homozygosity has previously been shown including hepatocellular and nonhepatocellular malignancies. This study was performed to compare frequencies of HFE C282Y and H63D variants in Turkish women with breast cancer and healthy controls.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
Archived DNA samples of Hacettepe University Oncology Institute were used in this study. The HFE gene was investigated by PCR-RFLP.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 364 366 364 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
All subjects studied were free from C282Y mutation. Thirty-nine patients had H63D mutation and were all heterozygous. H63D allele frequency was 22.2% (39/176) in the breast cancer patients, and 14% (28/200) in the healthy volunteers. Statistical analysis of cases with HFE H63D phenotype showed significant difference between breast cancer and healthy volunteers (P = 0.02).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Our results suggest that HFE H63D mutation frequencies were increased in the breast cancer patients in comparison to those in the general population. Also, odds ratios (odds ratio = 2.05) computed in this study suggest that H63D has a positive association with breast cancer.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-A </italic>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1142 1143 1142 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1284 1288 1284 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 1321 1322 1321 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1323 1324 1323 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1393 1394 1393 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1395 1396 1395 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1397 1398 1397 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1548 1549 1548 1549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
The hereditary hemochromatosis gene HFE (6p21.3) 4 Mb telomeric to the HLA-A locus, and its product has a structure similar to MHC class I molecules [1]. It has a critical role in iron homeostasis. The total number of HFE variants detected to date is at least 37, of which 19 are missense [2]. Two mutations, C282Y (the substitution of tyrosine for cysteine at position 282) and H63D (the substitution of aspartate for histidine at position 63), are particularly frequent among patients with hereditary hemochromatosis [1] that is characterized by hepatic fibrosis and cirrhosis, diabetes mellitus, skin pigmentation, hypogonadism, arthropathy and cardiomyopathy as a result of excessive iron absorption from the gut and subsequent accumulation of iron in organs. HFE protein forms a stable complex with transferrin receptor (TFR), thereby reducing its affinity for transferrin (TF) by approximately ten fold [3]. TF is the major iron transport protein in blood and TFR facilitates the uptake of ironbound transferrin. C282Y mutation prevents the association of the mutant HFE protein with TFR because of the lack of cell surface expression [4]. As a result, increased affinity of the uncomplexed TFR for TF causes higher iron absorption. The significance of the H63D mutation on the HFE gene was at first controversial [1,3]. Subsequent studies suggested a functional role for H63D mutation [3,5,6]. The H63D variant of the HFE protein does reach the cell surface and forms a stable complex with TFR but fails to control high TFR affinity for TF [7].
###end p 11
###begin p 12
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 623 627 623 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
HFE mutation frequencies show marked geographical differences throughout the world. Most Caucasian patients of Northwestern European ancestry with hereditary hemochromatosis are homozygous for C282Y [8,9]. Compound heterozygotes for the C282Y and H63D mutations expressing hemochromatosis are also observed, but with less penetrance than C282Y homozygotes [6,8]. Besides hepatocellular carcinoma [10,11] common malignancies, including hematological [12-14], colorectal cancer [15-17], and breast cancer [15,18] show risk associations with C282Y. However, there are contradictious studies showing no association between the HFE mutations and cancer risk [19-22].
###end p 12
###begin p 13
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
One possible mechanism for the association might be the load of reactive free iron molecules which may cause DNA damage [23,24], which may suppress the host defense cells and induce proliferation [25,26], and which may convert nitric oxide from a proapoptotic to an antiapoptotic molecule [27].
###end p 13
###begin p 14
###xml 94 102 <span type="species:ncbi:9606">patients</span>
The current report outlines our analysis of C282Y and H63D mutations in Turkish breast cancer patients and control subjects from the same geographical area.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Controls
###end title 16
###begin p 17
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 209 215 <span type="species:ncbi:9103">Turkey</span>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
###xml 404 409 <span type="species:ncbi:9606">women</span>
###xml 450 456 <span type="species:ncbi:9103">Turkey</span>
In this study, we used 88 archived DNA samples, which had been isolated from blood samples of patients with breast cancer diagnosed at Hacettepe University Oncology Institute Department of Medical Oncology in Turkey over the last ten years. The mean age at diagnosis for the breast cancer patients was 41 yr (range, 21-75). The population controls consisted of 100 DNA samples from voluntary and healthy women who lived in Ankara, located at central Turkey. The mean age of the controls was 33 yr (range, 21-70). This study has been approved by the Hacettepe University Ethics Committee.
###end p 17
###begin title 18
PCR-RFLP
###end title 18
###begin p 19
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
PCR amplification and electrophoresis were performed by using the standard procedures described previously [1,28]. The following general HFE primers were used at annealing temperature of 58degreesC and 57.4degreesC for analysis of C282Y and H63D mutations:
###end p 19
###begin p 20
C282Y-Forward; 5'-TGGCAAGGGTAAACAGATCC-3',
###end p 20
###begin p 21
C282Y-Reverse; 5'-CTCAGGCACTCCTCTCAACC-3',
###end p 21
###begin p 22
H63D-Forward; 5'-ACATGGTTAAGGCCTGTTGC-3',
###end p 22
###begin p 23
H63D-Reverse; 5'-GCCACATCTGGCTTGAAATT-3'.
###end p 23
###begin p 24
###xml 43 46 43 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rsa</italic>
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl</italic>
###xml 115 118 115 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rsa</italic>
###xml 328 331 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl</italic>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The amplified fragments were digested with RsaI for the C282Y and BclI for the H63D mutations. Upon digestion with RsaI, the 387 bp PCR product of C282Y region shows two fragments of 247 bp and 140 bp in normal DNA and two additional fragments of 111 bp and 29 bp in mutant DNA. The 294 bp H63D region PCR product digested with BclI generates fragments of 138 bp, 70 bp in normal DNA and 208 bp in mutant DNA [28]. PCR digests were analyzed on 2.5% agarose gels (Figure 1 and 2). The relative positions of the mutations analyzed in the present study are given in Table 1.
###end p 24
###begin title 25
Statistical analyses
###end title 25
###begin p 26
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 568 570 568 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 689 691 689 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
Frequencies of the HFE alleles were calculated by gene counting. Hardy-Weinberg equilibrium was tested before proceeding to the analysis. Statistical analysis of mutation prevalence in case and control groups was performed by using two-tailed Fisher's exact test. The proportions of patients with breast cancer and healthy volunteers who carried at least one mutant allele are presented with 95% confidence intervals (CIs) and Odds Ratio (OR). Analyses were performed by using Instat V2.02 (GraphPad Inc USA) statistical software package. In general group comparisons P value < 0.05 was accepted as statistically significant whereas in subgroup analysis after making Bonferroni adjustment P value < 0.0125 value was accepted as statistically significant.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 90 96 <span type="species:ncbi:9103">Turkey</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 423 428 <span type="species:ncbi:9606">women</span>
###xml 465 470 <span type="species:ncbi:9606">women</span>
According to the birth of place thirty-eight percent of the entire cases was from Central Turkey, twenty-eight percent was from South and West (Mediterranean region), twenty percent was from East, and fifteen percent was from North (Black Sea region). Information about cancer type and stages were available for 52 patients, and ninety-three percent of them had infiltrative ductal carcinoma and ninety-four percent of the women had limited-stage (stages I-III), 3 women (6%) had distant metastases at diagnosis.
###end p 28
###begin p 29
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 450 454 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 545 547 545 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 747 748 747 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1035 1039 1035 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 1170 1171 1170 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1232 1237 1232 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H63D </italic>
###xml 1268 1269 1268 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 150 155 <span type="species:ncbi:9606">women</span>
###xml 298 303 <span type="species:ncbi:9606">women</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
###xml 1065 1073 <span type="species:ncbi:9606">patients</span>
###xml 1207 1215 <span type="species:ncbi:9606">patients</span>
###xml 1350 1358 <span type="species:ncbi:9606">patients</span>
There was no significant deviation from Hardy-Weinberg equilibrium in the distribution of genotypes in the control group. In the control group of 100 women, HFE H63D allele frequency was 14%, and the frequency of HFE H63D-homozygosity was 1%. Overall allele frequency for breast cancer group of 88 women (71 sporadic and 17 familial), for HFE H63D was 22.2% whereas there were no HFE H63D-homozygotes in the group. Statistical analysis of cases with HFE H63D phenotype showed significant difference between breast cancer and healthy volunteers (P = 0.02, OR = 2.05, 95% CI = 1.12 to 3.75) whereas there was no significant difference between either familial breast cancer and healthy volunteers or familial and sporadic breast cancer groups (Table 3). Subgroup analysis showed that the difference between the cases and control groups is based on the sporadic cases (P = 0.0001, OR = 3.13, 95% CI = 1.65 to 5.94). Information for the pre- and post-menopausal status was available for only 64 patients. Statistical analysis of cases with HFE H63D mutation among these patients showed no significant differences between premenopasual and postmenopausal breast cancer (Table 3). Characteristics of breast cancer patients with respect to H63D allele are summarized in Table 2. There were also no statistically significant differences between breast cancer patients with and without the H63D allele with respect to age or heredity. All subjects studied were free from C282Y mutation.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 499 503 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 583 586 583 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE</italic>
###xml 716 718 716 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 106 111 <span type="species:ncbi:9606">women</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
As expected from previous population studies [29-31] we did not find any C282Y mutation among the Turkish women who participated in this study. The results of this case-control study showed that H63D was more common in breast cancer patients. Because endogenous estrogens are more closely related to postmenopausal breast cancer and iron might have a role at redox-cycling estrogen metabolites to produce hydroxyl radicals [32,33], we compared premenopasual and postmenopausal breast cancer for the HFE H63D mutation. Since significant iron loss stops with menopause, an increase in HFE-associated cancer risk might also be possible. Contrary, there was no statistically significant difference between these groups (P = 0.12).
###end p 31
###begin p 32
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE</italic>
###xml 293 295 293 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1041 1045 1041 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 1122 1124 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1344 1346 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 2082 2084 2082 2084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 2095 2097 2095 2097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 415 420 <span type="species:ncbi:9606">women</span>
###xml 593 598 <span type="species:ncbi:9606">women</span>
###xml 665 670 <span type="species:ncbi:9606">women</span>
###xml 1147 1152 <span type="species:ncbi:9606">women</span>
###xml 1639 1647 <span type="species:ncbi:9606">patients</span>
To the best of our knowledge, this is the second study that shows a significant association between female breast cancer and HFE-H63D although a subgroup analysis in a general cancer association study also revealed a non-significantly increased odds ratio for H63D carriers (n = 18, OR = 2.0, P = 0.14) in breast cancer [12]. A recent article, making the same comparisons of H63D mutation frequency between Russian women with breast cancer and controls, found age to be an important confounder of the association, wherein a positive association of H63D with breast cancer was only found among women over 57 years old [34]. Because of the insufficient number of the women over 45 years old in our study (Control N = 5, Cases N = 22), the estimation could be made in wide range which might cause unreliable interpretations. Therefore, age-specific analysis was not performed in this study. Another recent study showed no association between male breast cancer and H63D [35]. Although the lack of gender difference shown in association between HFE genotypes and medical conditions related to iron overload other than cancer [36], this variability in women with H63D mutations with respect to cancer risk could be the influence of potential modifier factors for breast cancer. The only other cancer association with H63D is with malignant gliomas [37]. If replicated elsewhere, further studies can be designed to distinguish between mechanistic possibilities. Our study had some limitations. We were unable to study the effect of H63D on serum iron parameters or gene and environment interactions, as we did not have stored serum samples from patients nor dietary or medication (oral contraceptives, etc) history. Ideally, a sample larger than ours should be studied in a genetic association study to rule out the chance factor. Not only is the study small, but when a small number of multiple comparisons are made, the power of the study is further diminished. When Bonferroni correction were made the comparison between the cases and controls in this study was no longer significant (p = 0.02 vs. a = 0.0125).
###end p 32
###begin p 33
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 74 80 <span type="species:ncbi:9103">Turkey</span>
We compared the data on H63D frequencies from other population studies in Turkey. Our control frequency from age-matched females is in general agreement with other results which are 13.6%, 11.6% respectively [29,30]. The only exception is the study by Simsek et al., which reported a higher H63D mutation frequency (24.9%) from predominantly male blood donors [31]. A larger control group consisting of truly population-based females would have yielded a more robust estimate of the frequency if we had had the resources to achieve that.
###end p 33
###begin p 34
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 170 175 <span type="species:ncbi:9606">human</span>
###xml 766 772 <span type="species:ncbi:9103">Turkey</span>
###xml 1180 1188 <span type="species:ncbi:9606">patients</span>
###xml 1215 1221 <span type="species:ncbi:9103">Turkey</span>
The role of H63D in iron homeostasis is well established. Although an animal study unambiguously showed an effect of H63D mutation on hemochromatosis development [38], a human twin study established the influence of H63D on transferrin saturation levels [39]. Significant increases in both transferrin saturation and serum ferritin levels in H63D heterozygotes versus HFE wild type controls have also been demonstrated in large population studies [40-42]. HFE H63D mutation is very variable worldwide. The carrier frequency of the H63D mutation is 21.6% in Europe, 5.4% in Africa/Middle-East, 2.8% Asia and 22.8% in America [9]. One possibility is that H63D association with breast cancer might have been a selection of a specific subgroup among Turkish population. Turkey has a very heterogeneous population whose ancestries are from Anatolia (east Mediterranean region), Middle East and Central Asia. Related or unrelated susceptibility gene mutations, especially the ones which show ethnic dependence may both arise at higher frequencies in a specific subgroup of the mix-population. However, being a reference center Hacettepe Oncology Institute has the potential to comprise patients from different regions of Turkey and therefore, it is less likely that a specific subgroup of the population has been selected for this study.
###end p 34
###begin p 35
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA</italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 371 375 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 622 626 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 634 638 634 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 767 769 767 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 801 803 801 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 845 848 845 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA</italic>
###xml 870 873 870 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA</italic>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1032 1036 1032 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 1040 1043 1040 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA</italic>
###xml 1070 1074 1070 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 1195 1199 1195 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 1222 1226 1222 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
###xml 1238 1242 1238 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 1268 1272 1268 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
Despite a large physical distance, the genetic distance between HFE and the telomeric end of the HLA complex is less than 1 cM. This results in linkage disequilibrium between H63D and HLA-A29 [43,44]. One alternative explanation is therefore confounding by locus, e.g., an HLA association may have appeared as H63D association in our study due to linkage disequilibrium. HLA loci have been studied in breast cancer and several associations have been reported but most importantly a recent large family study mapped a breast cancer susceptibility locus towards the telomeric end of the HLA complex [45]. The region between HFE and the HLA complex has another feature that may be relevant in the mechanism of an association with H63D. A significant correlation with CD8+ T-cell numbers, but not with CD4+ T-cell numbers, in subjects carrying both HLA-A29 and H63D or both HLA-A*01 and H63D mutation has been reported [44,46]. Thus, the H63D association may be a reflection of an immune response gene association in the region between HFE and HLA. Further large studies on HFE association with breast cancer susceptibility in populations lacking the C282Y mutation may need to include markers from HLA loci, loci between the HLA complex and HFE and other variants of the HFE gene for more meaningful results than our preliminary study has shown.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 53 58 <span type="species:ncbi:9606">women</span>
We did not find any C282Y mutation among the Turkish women who participated in this study. The results of this case-control study show that H63D has a positive association with breast cancer. However, when a small number of multiple comparisons are made, the power of the study is diminished. Ideally, a sample larger than ours should be studied in a genetic association study to rule out the chance factor.
###end p 37
###begin title 38
Competing interests
###end title 38
###begin p 39
The author(s) declare that they have no competing interests.
###end p 39
###begin title 40
Authors' contributions
###end title 40
###begin p 41
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
AGO designed the study, carried out the molecular genetic (PCR-RFLP) studies, performed the statistical analysis and drafted the manuscript. SAB participated in the PCR-RFLP studies. ENG is the medical oncologist who diagnosed breast cancer patients and gave the related information. DG provided DNA samples of the patients and control group and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 41
###begin title 42
Pre-publication history
###end title 42
###begin p 43
The pre-publication history for this paper can be accessed here:
###end p 43
###begin p 44

###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
###xml 163 171 <span type="species:ncbi:9606">patients</span>
This work was supported in part by Kirikkale University Research Found (KU AF 02/08.01.04) and Eczacibasi Scientific Research and Award Found. We thank the cancer patients and healthy volunteers who made this analysis possible. We also thank Professor M. Oguz Guc and Handan Camdeviren-Ankarali for reviewing the statistical analysis.
###end p 46
###begin article-title 47
###xml 44 52 <span type="species:ncbi:9606">patients</span>
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
###end article-title 47
###begin article-title 48
Hematologically important mutations: iron storage diseases
###end article-title 48
###begin article-title 49
The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding
###end article-title 49
###begin article-title 50
###xml 56 57 56 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The hemochromatosis founder mutation in HLA-H disrupts b2-microglobulin interaction and cell surface expression
###end article-title 50
###begin article-title 51
The significance of the 187G (H63D) mutation in hemochromatosis
###end article-title 51
###begin article-title 52
H63D is an haemochromatosis associated allele
###end article-title 52
###begin article-title 53
Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells
###end article-title 53
###begin article-title 54
Mutation analysis in hereditary hemochromatosis
###end article-title 54
###begin article-title 55
###xml 56 61 <span type="species:ncbi:9606">Human</span>
HFE gene and Hereditary Hemochromatosis: a HuGE review. Human Genome Epidemiology
###end article-title 55
###begin article-title 56
HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence
###end article-title 56
###begin article-title 57
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Mutations of the HFE gene in patients with hepatocellular carcinoma
###end article-title 57
###begin article-title 58
HFE C282Y and H63D in adults with malignancies in a community medical oncology practice
###end article-title 58
###begin article-title 59
The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia
###end article-title 59
###begin article-title 60
HFE gene mutations in susceptibility to childhood leukemia: HuGE review
###end article-title 60
###begin article-title 61
Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders
###end article-title 61
###begin article-title 62
Colorectal cancer and HFE gene mutations
###end article-title 62
###begin article-title 63
Evidence for association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk colorectal cancer
###end article-title 63
###begin article-title 64
###xml 64 69 <span type="species:ncbi:9606">Women</span>
Increased Prevalence of the HFE C282Y Hemochromatosis Allele in Women with Breast Cancer
###end article-title 64
###begin article-title 65
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders
###end article-title 65
###begin article-title 66
Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands)
###end article-title 66
###begin article-title 67
Hemochromatosis gene in leukemia and lymphoma
###end article-title 67
###begin article-title 68
Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer
###end article-title 68
###begin article-title 69
###xml 106 122 <span type="species:ncbi:562">Escherichia coli</span>
Role of iron and superoxide for generation of hydroxyl radical, oxidative DNA lesions, and mutagenesis in Escherichia coli
###end article-title 69
###begin article-title 70
Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation
###end article-title 70
###begin article-title 71
Immune cell functions in iron overload
###end article-title 71
###begin article-title 72
Iron inhibits the non-specific tumoricidal activity of macrophages: a possible contributory mechanism for neoplasia in hemochromatosis
###end article-title 72
###begin article-title 73
Influence of iron on in vivo proliferation and lethality of L 1210 cells
###end article-title 73
###begin article-title 74
Genotyping of hemochromatosis-associated mutations in the HFE gene by PCR-RFLP and a novel reverse hybridization method
###end article-title 74
###begin article-title 75
Global prevalence of putative haemochromatosis mutations
###end article-title 75
###begin article-title 76
###xml 33 39 <span type="species:ncbi:9103">Turkey</span>
Screening for hemochromatosis in Turkey
###end article-title 76
###begin article-title 77
###xml 173 179 <span type="species:ncbi:9103">Turkey</span>
Frequency of HFE mutations among Turkish blood donors according to transferrin saturation: genotype screening for hereditary hemochromatosis among voluntary blood donors in Turkey
###end article-title 77
###begin article-title 78
Role of iron in estrogen-induced cancer
###end article-title 78
###begin article-title 79
###xml 15 20 <span type="species:ncbi:9606">human</span>
Progression of human breast cancer to the metastatic state is linked to hydroxyl radical-induced DNA damage
###end article-title 79
###begin article-title 80
###xml 69 74 <span type="species:ncbi:9606">women</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers
###end article-title 80
###begin article-title 81
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients
###end article-title 81
###begin article-title 82
Hemochromatosis and iron-overload screening in a racially diverse population
###end article-title 82
###begin article-title 83
High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas
###end article-title 83
###begin article-title 84
###xml 44 50 <span type="species:ncbi:10090">murine</span>
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis
###end article-title 84
###begin article-title 85
Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins
###end article-title 85
###begin article-title 86
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA
###end article-title 86
###begin article-title 87
HFE mutations, iron deficiency and overload in 10,500 blood donors
###end article-title 87
###begin article-title 88
Contribution of different HFE genotypes to iron overload disease: a pooled analysis
###end article-title 88
###begin article-title 89
Major histocompatibility complex class I associations in iron overload: evidence for a new link between the HFE H63D mutation, HLA-A29, and non-classical forms of hemochromatosis
###end article-title 89
###begin article-title 90
Co-selection of the H63D mutation and the HLA-29 allele: a new paradigm of linkage disequilibrium?
###end article-title 90
###begin article-title 91
The HLA class III subregion is responsible for an increased breast cancer risk
###end article-title 91
###begin article-title 92
###xml 123 129 <span type="species:ncbi:9606">humans</span>
Involvement of the Major Histocompatibility Complex region in the genetic regulation of circulating CD8+ T-cell numbers in humans
###end article-title 92
###begin title 93
Figures and Tables
###end title 93
###begin p 94
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Determination of H63D mutation of the <italic>HFE </italic>gene by restriction enzyme analysis</bold>
Determination of H63D mutation of the HFE gene by restriction enzyme analysis. Molecular weight marker (MW) sizes are shown on the first lane.
###end p 94
###begin p 95
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE </italic>
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Determination of C282Y mutation of the <italic>HFE </italic>gene by restriction enzyme analysis</bold>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
Determination of C282Y mutation of the HFE gene by restriction enzyme analysis. Neither homozygote nor heterozygote C282Y mutations were found in patients or in healthy controls.
###end p 95
###begin p 96
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HFE</italic>
HFE mutations with nucleotide changes and their positions within HFE
###end p 96
###begin p 97
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Characteristics of breast cancer patients
###end p 97
###begin p 98
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Psi Heterozygous patients for H63D allele.
###end p 98
###begin p 99
###xml 3 8 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wt/Wt</italic>
xi Wt/Wt, homozygous wild-type.
###end p 99
###begin p 100
###xml 2 10 <span type="species:ncbi:9606">Patients</span>
* Patients diagnosed at younger than 40 years.
###end p 100
###begin p 101
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
Statistical analysis of cases with H63D mutation. Analysis between Total breast cancer patients and Healthy controls, Sporadic breast cancer patients and Healthy controls, Familial breast cancer patients and Healthy controls, Sporadic breast cancer and Familial breast cancer patients, Premenopausal and Postmenopausal breast cancer patients are shown. One healthy volunteer was homozygous for the mutation; all other subjects listed here were heterozygous. All the subjects studied were free from C282Y mutation.
###end p 101

